HIGH GRADE GLIOMA

This early-stage trial is testing a new type of cell therapy for aggressive brain tumors that have returned or stopped responding to standard treatments. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to better recognize and attack cancer ce…

This early-stage trial is testing the safety and best doses of two oral drugs, trametinib and everolimus, given together to children and young adults whose brain tumors have come back after prior treatment. The study aims to see if blocking two different tumor growth pathways at …

This study is testing a new oral medication called LAM561 for children under 18 with advanced, hard-to-treat cancers, including aggressive brain tumors. The main goals are to find a safe daily dose and see how well the body handles the drug. If the treatment shows benefit, childr…

This study is testing a new vaccine designed to train the immune system to fight aggressive brain cancers in children and young adults. It will enroll about 120 patients aged 3 to 39 with newly diagnosed high-grade glioma, diffuse intrinsic pontine glioma (DIPG), or recurrent med…

This study is testing a drug called Lutathera in children and young adults (ages 4 to 39) with aggressive brain or spinal cord tumors that have come back or gotten worse after standard treatments. Lutathera is a targeted radiation therapy that seeks out and attaches to specific m…

This is an early-stage trial testing a new type of personalized immune cell therapy called TX103 CAR-T in adults with a specific, aggressive brain cancer (grade 4 glioma) that has returned or worsened after standard treatment. The main goal is to find a safe dose and see how well…

This is a first-in-human study testing a new type of cell therapy for adults with recurrent or progressive glioblastoma or other high-grade brain tumors. The therapy uses modified natural killer (NK) immune cells designed to recognize two specific markers on the patient's tumor. …

This study is testing whether adding two new drugs, DB107-RRV and DB107-FC, to standard brain cancer treatment helps patients live longer without their cancer worsening. The trial will enroll 70 adults with newly diagnosed aggressive brain tumors who are having surgery. Researche…

This study aims to find better treatments for children and young adults newly diagnosed with aggressive brain tumors. Researchers will analyze the genetic makeup of each patient's tumor to match them with a targeted therapy that might work best for their specific cancer. The goal…

This study is testing a targeted drug called lorlatinib in children and young adults (ages 1-21) newly diagnosed with aggressive brain tumors (high-grade gliomas) that have specific genetic changes called ALK or ROS1 fusions. The main goals are to see if the drug can control the …

This study is testing two different drug combinations to see if they can help children and young adults with aggressive brain tumors live longer. The trial is for patients who have just finished radiation therapy. One group receives two drugs (ribociclib and everolimus), while an…

This early-stage study is testing the safety of combining an oral drug called azeliragon with full brain and spine radiation in patients with aggressive cancer that has spread to the lining of the brain and spinal cord. The main goal is to find out if this combination is safe and…

This study continues to monitor patients who have already completed previous cancer treatment studies with dabrafenib and/or trametinib. It tracks 100 patients with various cancers including melanoma and lung cancer to understand the long-term safety of these medications. The goa…

This early-stage study is testing a drug called larotrectinib in children and young adults (up to age 21) newly diagnosed with aggressive brain tumors that have a specific genetic feature called an NTRK fusion. The main goals are to see if the drug can control the tumor and to ch…

This early-stage study is testing an experimental drug called BDTX-1535 in people with aggressive brain tumors (high-grade glioma or glioblastoma) that have specific genetic changes in a protein called EGFR. The research aims to see if the drug reaches brain tumor tissue effectiv…

This study is testing a targeted drug called entrectinib as the first treatment for children under 3 years old who have aggressive brain tumors with specific genetic changes (NTRK or ROS1 fusions). The main goal is to see how well the drug shrinks these tumors. Researchers will a…

This early-stage study is testing a new type of personalized immune therapy called B7-H3-CAR T cells for children and young adults (up to age 21) with brain tumors that have come back or haven't responded to standard treatments. The therapy involves collecting a patient's own imm…

This early-stage study is testing a new drug called XRD-0394 in combination with standard radiation therapy for patients with aggressive brain tumors (high-grade gliomas). The main goal is to find a safe and tolerable dose of the drug. Researchers will also look for early signs o…

This early-stage study is testing the safety and initial effects of a new oral medicine, PF-07799544, when taken with another drug, PF-07799933. It is for adults with advanced solid tumors, like melanoma or lung cancer, that have a specific genetic change called a BRAF V600 mutat…

This study is testing whether a special type of PET scan using a tracer called 18F-fluciclovine can help doctors more accurately tell if a child's aggressive brain tumor is actually growing again or if the changes seen on a regular MRI are just a temporary reaction to treatment. …

This study is testing a new type of brain scan to see if it can better detect any remaining cancer in patients with high-grade glioma after they finish standard radiation therapy. About 20 adult and pediatric patients will receive two special PET/MRI scans to look for active tumo…

This study is testing a new, smarter biopsy needle designed to make brain tumor sampling safer and more accurate. The tool uses special lights and sound to help doctors see tumor tissue and avoid tiny blood vessels in real-time. Researchers will test it on about 20 tumor samples …

This study aims to create a living collection of 3D models grown from patients' brain tumors (gliomas). Researchers will use these models to understand why these tumors are hard to treat, become more aggressive, and resist therapies like radiation and chemotherapy. The long-term …

This study aims to see if PET scans and blood tests can help predict which brain cancer patients might experience thinking and memory problems after radiation treatment. Researchers will follow 16 adults with high-grade glioma who are scheduled for standard radiation and chemothe…

This study aims to understand if the electrical activity in and around aggressive brain tumors can predict where the cancer will spread next. During standard surgery, researchers will safely record brain signals and take small tissue samples from 10 adult patients. The goal is to…